Roche will nominate Illumina board candidates

Roche ($RHHBY) has upped the ante in its $5.7 billion hostile bid for gene sequencing company Illumina ($ILMN). Bloomberg is reporting that the company wants to boost the number of members on Illumina's board to 11 directors from 9, and nominate 6 independent candidates to the board of directors during its annual meeting later this year. As a result, Roche said, shareholders could elect a majority of directors nominated by Roche. The board meeting hasn't been scheduled yet. Illumina, in response to the bid, adopted a "poison bill" shareholder rights plan that could make Roche's bid too expensive. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.